HAWA THERAPEUTICS LLC

Athens, GA · Biotech · Private

Small-molecule HIF2A inhibitor (PT2385) formulated for topical and injection delivery to treat muscle strain injuries

Grants
$245K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Feasibility Study of HIF2A Inhibitor PT2385 to Treat Muscle Strain Injury$245,050
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3212General Presence Inc.—$5K
3213P2D, INC——
3214Artios Pharma——
3215HAWA THERAPEUTICS LLC——
3216Poplar Therapeutics——
3217MULTITARGA LLC——
3218Shield Pharma LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.